Photo generated from www.esmoopen.com
Mar 21, 2024, 10:54
The Swedish SCAN-B cohort, the HER2DX risk-score was found significantly associated with OS after adjustment for clinical variables and treatment regimen – ESMO Open
ESMO Open posted on X:
“Hot off the press: among 757 patients with early HER2+ breast cancer in the Swedish SCAN-B cohort, the HER2DX risk-score as a continuous variable was found significantly associated with OS after adjustment for clinical variables and treatment regimen.”
Read Further
Source: ESMO Open/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 18:02
Dec 22, 2024, 17:54
Dec 22, 2024, 17:51
Dec 22, 2024, 17:47
Dec 22, 2024, 17:44
Dec 22, 2024, 17:39
Dec 22, 2024, 17:36
Dec 22, 2024, 17:32
Dec 22, 2024, 17:18